Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.82 |
| ▸ | GAA | P10253 | 4/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.50 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.50 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31435118 | 0.90 | NLRP3 (1.00) | NLRP3GAAALDH1A1L3MBTL1TSHR | |
| SCHEMBL20702997 | 0.90 | NLRP3 (1.00) | NLRP3GAAALDH1A1L3MBTL1TSHR | |
| SCHEMBL4767657 | 0.88 | NLRP3 (0.69) | NLRP3GAAALDH1A1L3MBTL1TSHR | |
| SCHEMBL6538988 | 0.86 | NLRP3 (0.62) | NLRP3GAAALDH1A1L3MBTL1HPGD | |
| SCHEMBL4773984 | 0.85 | NLRP3 (0.66) | NLRP3GAAALDH1A1L3MBTL1TSHR | |
| SCHEMBL11537068 | 0.85 | GAA (1.00) | NLRP3GAAALDH1A1L3MBTL1TSHR | |
| SCHEMBL6415965 | 0.84 | NLRP3 (0.64) | NLRP3GAAALDH1A1L3MBTL1TSHR | |
| SCHEMBL514620 | 0.83 | GAA (0.67) | NLRP3GAAALDH1A1L3MBTL1TSHR | |
| SCHEMBL7505227 | 0.83 | CYP1A2 (0.67) | NLRP3GAAALDH1A1L3MBTL1TSHR | |
| SCHEMBL404869 | 0.83 | CYP1A2 (0.67) | NLRP3GAAALDH1A1L3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114380718-B | Acylation method of aniline compound | 河南农业大学 | 2022-09-30 | — | — | CN | disclosed |
| CN-114380718-A | Acylation method of aniline compound | 河南农业大学 | 2022-04-22 | — | — | CN | disclosed |
| US-20220017524-A1 | ARYL HYDROCARBON RECEPTOR (AHR) ACTIVATOR COMPOUNDS AS CANCER THERAPEUTICS | THE BROAD INSTITUTE, INC. (US) | 2022-01-20 | — | — | US | disclosed |
| WO-2016024096-A1 | ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2016-02-18 | — | — | WO | disclosed |
| WO-2015088565-A1 | P2X4 RECEPTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015088565-A1 | P2X4 RECEPTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015088564-A1 | P2X4 RECEPTOR MODULATING COMPOUNDS | SUNOVION PHARMACEUTICALS INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| US-8293730-B2 | Substituted imidazo[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20100075954-A1 | SUBSTITUTED IMIDAZO[1,5-A][1,2,4]TRIAZOLO[1,5-D][1,4]BENZODIAZEPINE DERIVATIVES | KNUST HENNER | 2010-03-25 | — | — | US | disclosed |
| US-7671048-B2 | Substituted imidazo [1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20050261288-A1 | Tetracyclic lactam derivatives and uses thereof | INOTEK PHARMACEUTICALS CORPORATION | 2005-11-24 | — | — | US | disclosed |
| WO-2005082079-A2 | TETRACYCLIC LACTAM DERIVATIVES AND USES THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2005-09-09 | — | — | WO | disclosed |
| WO-2005042501-A1 | NOVEL NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20050096327-A1 | Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders | WARNER-LAMBERT COMPANY LLC | 2005-05-05 | — | — | US | disclosed |
| EP-1001934-A1 | INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER PHARMACEUTICALS INC. (JP) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999005104-A1 | INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-02-04 | — | — | WO | disclosed |
| US-4713383-A | ADENOSINE AND BENZODIAZEPINE ANTAGONISTS | CIBA-GEIGY CORPORATION (US) | 1987-12-15 | — | — | US | disclosed |
| EP-0227451-A2 | 5,6-Dialkoxy-4-imino-2 (1H)quinazolinone derivatives | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-07-01 | — | — | EP | disclosed |
| US-4668787-A | CARDIOTONIC | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-05-26 | — | — | US | disclosed |
| EP-0181282-A1 | Triazoloquinazoline compounds | CIBA-GEIGY AG (CH) | 1986-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096327-A1 | Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders | SLC6A2, SLC18A2, SLC6A3 | NLRP3 2828/4885GAA 2064/4885ALDH1A1 730/4885 |
| US-20050261288-A1 | Tetracyclic lactam derivatives and uses thereof | PARK7, GLS, IAPP | NLRP3 547/4885GAA 116/4885ALDH1A1 1205/4885 |
| US-20220017524-A1 | ARYL HYDROCARBON RECEPTOR (AHR) ACTIVATOR COMPOUNDS AS CANCER THERAPEUTICS | AHR, ESRRA, AR | NLRP3 3248/4885GAA 4082/4885ALDH1A1 395/4885 |
| US-20100075954-A1 | SUBSTITUTED IMIDAZO[1,5-A][1,2,4]TRIAZOLO[1,5-D][1,4]BENZODIAZEPINE DERIVATIVES | GABRA1, GABRA5, ADRA1A | NLRP3 1550/4885GAA 805/4885ALDH1A1 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.